MedX Health Corp. Announces Executive Changes

The Board of Directors of MedX Health Corp. ("MedX" or the "Company") (TSX
VENTURE:MDX) is pleased to announce the following Senior Executive changes. 


Gary Van Nest will retire as Chairman, and remain as a Director of the Company. 

Steven Guillen, MBA, the current Chief Executive Officer (CEO), and a Director,
will become Chairman of the Board. 


Robert von der Porten, MBA, of Toronto, a well-known and respected Senior
Operating Executive, also well experienced in finance, corporate development,
strategy, and implementation over a broad range of industries, will become,
President & Chief Executive Officer (CEO), and a Director of the Corporation. 


Louie Canitano, B.Sc, currently President and Chief Operating Officer (COO),
will continue the role of Chief Operating Officer (COO) of the Corporation. 


Jim Cooke, CPA, CA, will become Chief Financial Officer (CFO) of the
Corporation. Jim is an experienced financial executive and has worked with large
and small companies in a variety of industries, in all phases of the corporate
growth cycle. 


These appointments reflect the dimensions of the business opportunity currently
facing MedX as it launches into the skin cancer screening marketplace on a
global basis and the need for experienced operational talent at the executive
level in order to maximize the business opportunities at hand. 


"MedX has a world class technology to assist in the screening and detection of
skin cancers offering significant benefits to communities around the world in
which we plan to introduce it to: I am very excited to have the opportunity to
be part of this" said Mr. von der Porten. 


These appointments, which have been approved by the Board of Directors of MedX,
are subject to all relevant regulatory and other consents and approvals.


About MedX 

MedX, headquartered in Mississauga, Ontario (Toronto), and is a global leader in
the design, manufacturing and distribution of quality low level laser and light
therapy technologies for use in numerous medical settings, including
rehab/chiropractic, dental, wound care, and veterinary medicine, providing
patients with drug free and non-invasive treatment of tissue damage and pain.
MedX laser and light products are FDA approved, Health Canada cleared, and CE
Mark approved for use in North America as well as the European Union. MedX
Health acquired the worldwide assets of SIMSYS(TM) and MoleMate(TM) in June,
2011. For a complete profile of MedX and its products visit www.medxhealth.com.


About SIMSYS(TM) and MoleMate(TM) Skin Cancer Imaging 

SIMSYS(TM) and MoleMate(TM) received approval from Health Canada, and are
available for all Canadian physicians and dermatologist. SIMSYS(TM) and
MoleMate(TM) is also FDA approved for use in the USA and is currently under
review for CE approval for use in Europe, the UK, and Australia. For more
information log onto: www.simsys-molemate.com and click on 'See More', and see
approximately 2mm below the surface of suspicious moles and lesions with
additional information and images related to every mole and lesions associated
with all types of melanomas and non-melanomas. SIMSYS(TM) and MoleMate(TM) is an
optical biopsy that uses patented technology that features a hand-held scanner
device designed for clinical office use that utilizes light to view beneath
suspicious moles or lesions in a pain free, non-invasive manner, creating images
in real-time for physicians and dermatologist to evaluate all types of moles or
lesions within seconds, providing images that can reveal if a mole or lesion is
benign, or something more serious, often eliminating the need for skin biopsies,
resulting in less pain, scarring, and expense. Physicians and dermatologist
interested in learning more should contact MedX Health Corp. or log onto
www.simsys-molemate.com. 


This press release may contain forward-looking statements, including statements
regarding the business and anticipated financial performance of MedX Health
Corp., which involve risks and uncertainties. These risks and uncertainties may
cause MedX's actual results to differ materially from those contemplated by the
forward-looking statements. No stock exchange, securities commission or other
regulatory authority has approved or disapproved the information contained
herein. 


The TSX Venture Exchange has not reviewed and does not accept responsibility for
the adequacy or accuracy of this press release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Investors:
MedX Health Corp.
Robert von der Porten
President and CEO
905 670 4428
investor@medxhealth.com
Medx Health (TSXV:MDX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024